SCHEMBL29636288

SCHEMBL29636288

CC(C)Oc1ccc(B(O)O)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
ACACB O00763 12/20 0.40
PDE10A Q9Y233 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
CHRNA7 P36544 1/20 0.38
ACACA Q13085 7/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL561514 1.00 ALDH1A1 (0.45) ALDH1A1ACACBPDE10APIK3CDPIK3CA
SCHEMBL30525517 0.81 DAO (0.37) ACACBPIK3CDPIK3CAPIK3CB
SCHEMBL248140 0.81 DAO (0.37) ACACBPIK3CDPIK3CAPIK3CB
SCHEMBL17646787 0.80 LPL (0.32)
SCHEMBL22117678 0.79 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3402397 0.79
SCHEMBL4942 0.79 ENPP2 (0.48) ALDH1A1
SCHEMBL29643889 0.79 ENPP2 (0.48) ALDH1A1
SCHEMBL15051440 0.77 ACACB (0.37) ALDH1A1ACACBPDE10APIK3CDPIK3CA
Hydrochloric Acid SCHEMBL1870385 0.77 ENPP2 (0.47) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025104079-A1 SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-05-22 WO disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
WO-2022108849-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 ALDH1A1 1131/4885ACACB 2179/4885PDE10A 4119/4885
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS C3AR1, C9, C1R ALDH1A1 514/4885ACACB 309/4885PDE10A 3139/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S ALDH1A1 1146/4885ACACB 1961/4885PDE10A 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.